Souvenaid
 |
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
Souvenaid is a Medical food marketed for Alzheimer's disease by Danone (called Dannon in the US), consisting of a cocktail of nutrients including uridine monophosphate, choline, the omega-3 fatty acids EPA and DHA, phospholipids, B vitamins and antioxidants. As of January, 2010, Souvenaid is still being studied in clinical trials, and is not being sold commercially; details can be found at the product website.
The results of its first clinical trial were announced at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in July 2008[1][2]; the results were later published in the journal Alzheimer's & Dementia.[3]
The basic ideas behind this treatment were developed at the lab of Prof. Richard Wurtman of M.I.T.
Concerns have been expressed regarding possible conflicts of interests for this research.
[edit] Notes
- ^ ICAD Press Release
- ^ Alzheimer Research Forum news report
- ^ http://www.alzheimersanddementia.org/article/PIIS1552526009023292/abstract
- http://www.cnn.com/2010/HEALTH/01/08/alzheimer.drink.scan/index.html CNN article on Souvenaid
http://www.medscape.com/viewarticle/716581?src=mpnews&uac=77055EV&spon=26
- http://bmartinmd.com/2010/01/souvenaid-study-problematic.html Souvenaid study problematic
